Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Hemlibra emicizumab Bleeding prevention, hemophilia A Reimburse with clinical criteria and/or conditions Complete
Hepsera Adefovir dipivoxil Hepatitis B Do not list Complete
Hepsera Adefovir dipivoxil Hepatitis B List with clinical criteria and/or conditions Complete
Holkira Pak Ombitasvir/paritaprevir/ritonavir and dasabuvir Hepatitis C, chronic List with clinical criteria and/or conditions Complete
Holkira Pak ombitasvir/paritaprevir/ritonavir and dasabuvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Humira Adalimumab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete
Humira Adalimumab Arthritis, Psoriatic List with clinical criteria and/or conditions Complete
Humira Adalimumab Ankylosing spondylitis (AS) List with clinical criteria and/or conditions Complete
Humira Adalimumab Arthritis, juvenile idiopathic List with clinical criteria and/or conditions Complete
Humira Adalimumab Crohn's disease List with clinical criteria and/or conditions Complete
Humira Adalimumab Psoriasis List with clinical criteria and/or conditions Complete
Humira Adalimumab ulcerative colitis Withdrawn
Humira Adalimumab Ulcerative colitis Do not list at the submitted price Complete
Humira Adalimumab Hidradenitis suppurativa Reimburse with clinical criteria and/or conditions Complete
HyQvia immune globulin human and recombinant human hyaluronidase Humoral immunodeficiency Reimburse with clinical criteria and/or conditions Complete
Ibrance Palbociclib Withdrawn
Ibrance (with Faslodex) Palbociclib (with Fulvestrant) Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Complete
Ibrance Resubmission Palbociclib Advanced breast cancer Reimburse with clinical criteria and/or conditions Complete
Iclusig Ponatinib Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia Reimburse with clinical criteria and/or conditions Complete
Idhifa Enasidenib Acute myeloid leukemia (AML) Do not reimburse Complete
Ikervis cyclosporine keratitis, severe Withdrawn
Ilaris Canakinumab Cryopyrin-Associated Periodic Syndrome Do not list Complete
Ilaris Canakinumab Systemic Juvenile Idiopathic Arthritis Reimburse with clinical criteria and/or conditions Complete
Ilumya tildrakizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Iluvien fluocinolone acetonide Diabetic macular edema (DME) Withdrawn